Cortical beta- and alpha 2- adrenoceptor binding, hypothalamic noradrenaline and pineal melatonin concentrations measured at different times of the day after repeated treatment of rats with imipramine, zimeldine, alaproclate and amiflamine.
The effect of repeated treatment of rats for 21 days with the monoamine reuptake inhibitors imipramine, zimeldine, alaproclate (in each case 10 mumol/kg b.i.d.) and the reversible monoamine oxidase-A inhibitor amiflamine (3 mumol/kg b.i.d.) on brain noradrenergic mechanisms measured at different times of the day and night was investigated. Imipramine treatment produced a down-regulation of the Bmax for 3H-dihydroalprenolol binding to cortical beta-adrenoceptors that was not dependent upon the time of day the animals were killed. Zimeldine, on the other hand, reduced both Bmax and Kd of binding for day-time, but not night-time samples. Alaproclate and amiflamine were without effect on the binding. Twenty-four hour mean values for 1 nM 3H-p-aminoclonidine binding to alpha 2-adrenoceptors were lower for the zimeldine-treated rats than for the saline-treated rats. Pineal melatonin concentrations, which are regulated by beta-adrenoceptors, showed a pronounced diurnal rhythm, with the highest concentrations being found at 02:00. At this time point, a lower pineal melatonin content was found after amiflamine treatment, whereas imipramine, zimeldine and alaproclate were without significant effect. The importance of the use of more than one time point and the use of more than one biochemical test for the determination of the effects of repeated antidepressant treatment on central noradrenergic systems measured ex vivo is discussed.
D000409:Alanine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002540:Cerebral Cortex / Q000032:analysis*; D002940:Circadian Rhythm; D004082:Dihydroalprenolol / Q000378:metabolism; D007031:Hypothalamus / Q000032:analysis*; D007099:Imipramine / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008550:Melatonin / Q000032:analysis; D009638:Norepinephrine / Q000032:analysis; D010627:Phenethylamines / Q000494:pharmacology; D010870:Pineal Gland / Q000032:analysis*; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects* / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000378:metabolism; D015031:Zimeldine / Q000494:pharmacology
D000928:Antidepressive Agents; D010627:Phenethylamines; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D015031:Zimeldine; D004082:Dihydroalprenolol; C025293:alaproclate; D008550:Melatonin; C031466:amiflamine; D000409:Alanine; D007099:Imipramine; D009638:Norepinephrine